Abstract
Introduction: The anthracycline doxorubicin (DOX) has proved to be one of the most widely used and most effective antitumor drugs since its emergence in the 1960s. However, the utility of DOX is compromised by its potential lethal cardiotoxicity. In this review we summarize development in prevention and management of DOX-induced cardiotoxicity comprehensively.
Background: Strategies to enhance DOX efficacy in cancer cells while minimizing associated cardiotoxicity may prove clinically valuable. Employment of DOX derivatives, including currently available mitoxantrone and epirubicin, has been testified in several clinical trials. Several cardioprotective agents, including dexrazoxane, statins, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, and etc., have been developed and tested in animal and clinical trials.
Conclusion: Several strategies have been reported on the prevention and management of DOX-elicited cardiotoxicity, and many of them await verification from large scale clinical trials. Dexrazoxane has been approved to prevent and treat side effects of DOX, although concerns still exist that it might increase incidence of some kind of malignant tumors. Promising findings in autophagy, RNA binding protein quaking and statins encourage further research developing strategies by which heart protection and cancer cell killing are achieved simutaneously.
Keywords: Cardiotoxicity, doxorubicin, RNA-binding protein Quaking, statins.
Mini-Reviews in Medicinal Chemistry
Title:Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Volume: 17 Issue: 1
Author(s): Hao Liu, Haiyan Wang, Dingcheng Xiang and Wangang Guo
Affiliation:
Keywords: Cardiotoxicity, doxorubicin, RNA-binding protein Quaking, statins.
Abstract: Introduction: The anthracycline doxorubicin (DOX) has proved to be one of the most widely used and most effective antitumor drugs since its emergence in the 1960s. However, the utility of DOX is compromised by its potential lethal cardiotoxicity. In this review we summarize development in prevention and management of DOX-induced cardiotoxicity comprehensively.
Background: Strategies to enhance DOX efficacy in cancer cells while minimizing associated cardiotoxicity may prove clinically valuable. Employment of DOX derivatives, including currently available mitoxantrone and epirubicin, has been testified in several clinical trials. Several cardioprotective agents, including dexrazoxane, statins, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, and etc., have been developed and tested in animal and clinical trials.
Conclusion: Several strategies have been reported on the prevention and management of DOX-elicited cardiotoxicity, and many of them await verification from large scale clinical trials. Dexrazoxane has been approved to prevent and treat side effects of DOX, although concerns still exist that it might increase incidence of some kind of malignant tumors. Promising findings in autophagy, RNA binding protein quaking and statins encourage further research developing strategies by which heart protection and cancer cell killing are achieved simutaneously.
Export Options
About this article
Cite this article as:
Liu Hao, Wang Haiyan, Xiang Dingcheng and Guo Wangang, Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity, Mini-Reviews in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1389557516666160621083659
DOI https://dx.doi.org/10.2174/1389557516666160621083659 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Determinants of Severe Respiratory Syncytial Virus Infection and Post-Bronchiolitis Wheeze: A Systematic Review
Current Respiratory Medicine Reviews The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry Targeting Mitochondria for Cardiac Protection
Current Drug Targets Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology Multidrug Resistance Associated Proteins as Determining Factors of Pharmacokinetics and Pharmacodynamics of Drugs
Current Drug Metabolism Evolving Concepts Concerning Cardiac β-Adrenoceptor Function in Heart Failure
Current Pharmaceutical Design Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: Cardiac Imaging in the Diagnosis of Coronary Artery Disease: A Comprehensive Overview of Various Imaging Modalities)
Current Medical Imaging Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials Toll-Like Receptors and Myocardial Ischemia/Reperfusion, Inflammation, and Injury
Current Cardiology Reviews